Skip to main content

Table 1 Baseline characteristics of the patients

From: Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis

Characteristics Number (proportion,%) Characteristics Number (proportion,%)
Sex   Hemihepatic HCCc  
Male 52 (96.3) Yes 30 (55.6)
Female 2 (3.7) No 24 (44.4)
Age (years)   Distant metastasis  
≥ 55 18 (33.3) Yes 14 (25.9)
< 55 36 (66.7) No 40 (74.1)
Hepatitis B   PVTTd  
Yes 52 (96.3) Type III 44 (81.5)
No 2 (3.7) Type IV 10 (18.5)
AFPa ( ng/ml)   Tumor diameter  
≥400 29 (53.7) > 10 cm 27 (50.0)
<400 25 (46.3) ≤ 10 cm 27 (50.0)
Child-Pugh grade   Number of tumors  
A 42 (77.8) Single 5 (9.3)
B 12 (22.2) Multiple 49 (90.7)
ECOG PSb   Previous treatment  
0/1 42 (77.8) Yes 14 (25.9)
2 12 (22.2) No 40 (70.5)
Hepatic arterioportal fistulas   Postoperative treatment  
Yes 34 (73.0) Yes 36 (66.7)
No 20 (37.0) No 18 (33.3)
  1. aAFP alpha fetoprotein
  2. bECOG PS Cooperative Oncology Group performance status
  3. cHCC hepatocellular carcinoma
  4. dPVTT portal vein tumor thrombosis